A phase 2 trial evaluating the effect of Everolimus alternating with Sunitinib on progression-free survival in patients with advanced renal cell carcinoma
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Everolimus (Primary) ; Sunitinib
- Indications Renal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms EVERSUN
- Sponsors Novartis Pharmaceuticals
- 11 Jun 2015 Status changed from discontinued to completed as per Australian New Zealand Clinical Trials Registry.
- 24 Apr 2014 Status changed from active, no longer recruiting to discontinued.
- 01 Feb 2014 Primary endpoint 'Progression-free-survival-rate' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History